These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

231 related items for PubMed ID: 29800007

  • 21. Late presentation of generalised bullous pemphigoid-like reaction in a patient treated with pembrolizumab for metastatic melanoma.
    Parakh S, Nguyen R, Opie JM, Andrews MC.
    Australas J Dermatol; 2017 Aug; 58(3):e109-e112. PubMed ID: 27170423
    [Abstract] [Full Text] [Related]

  • 22. Pembrolizumab-Induced Alopecia Areata.
    Elshimy N, Blakeway E, Mitra A.
    Skinmed; 2019 Aug; 17(2):142-143. PubMed ID: 31145074
    [No Abstract] [Full Text] [Related]

  • 23. Association of Anti-Programmed Cell Death 1 Cutaneous Toxic Effects With Outcomes in Patients With Advanced Melanoma.
    Quach HT, Dewan AK, Davis EJ, Ancell KK, Fan R, Ye F, Johnson DB.
    JAMA Oncol; 2019 Jun 01; 5(6):906-908. PubMed ID: 30998826
    [Abstract] [Full Text] [Related]

  • 24. Lupus-like cutaneous reaction following pembrolizumab: An immune-related adverse event associated with anti-PD-1 therapy.
    Shao K, McGettigan S, Elenitsas R, Chu EY.
    J Cutan Pathol; 2018 Jan 01; 45(1):74-77. PubMed ID: 29028121
    [Abstract] [Full Text] [Related]

  • 25. Third-line pembrolizumab-induced immune-related interstitial pneumonitis after ipilimumab and nivolumab failure.
    Oya K, Nakamura Y, Fujisawa Y, Endo R, Tanaka R, Ishitsuka Y, Maruyama H, Watanabe R, Okiyama N, Fujimoto M.
    Eur J Dermatol; 2018 Feb 01; 28(1):129-130. PubMed ID: 29400284
    [No Abstract] [Full Text] [Related]

  • 26. Development of Poliosis Following Checkpoint Inhibitor Treatment for Cutaneous Melanoma.
    Ediriwickrema LS, Liu CY, Kikkawa DO, Korn BS.
    Ophthalmic Plast Reconstr Surg; 2019 Feb 01; 35(5):e121-e122. PubMed ID: 31373986
    [Abstract] [Full Text] [Related]

  • 27. Ipilimumab prolongs survival in advanced melanoma.
    Burki TK.
    Lancet Oncol; 2016 Nov 01; 17(11):e481. PubMed ID: 27746107
    [No Abstract] [Full Text] [Related]

  • 28. Cutaneous lupus associated with pembrolizumab therapy for advanced melanoma: a report of three cases.
    Blakeway EA, Elshimy N, Muinonen-Martin A, Marples M, Mathew B, Mitra A.
    Melanoma Res; 2019 Jun 01; 29(3):338-341. PubMed ID: 30762712
    [Abstract] [Full Text] [Related]

  • 29. Fulminant response to combined checkpoint inhibition with ipilimumab plus nivolumab after failure of nivolumab monotherapy in metastatic melanoma.
    Ugurel S, Kiecker F, Fröhling S, Wetter A, Bankfalvi A, Sucker A, Zimmer L, Livingstone E, Roesch A, Becker JC, Schadendorf D.
    Eur J Cancer; 2017 Sep 01; 83():142-145. PubMed ID: 28735071
    [No Abstract] [Full Text] [Related]

  • 30. Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.
    Hamid O, Puzanov I, Dummer R, Schachter J, Daud A, Schadendorf D, Blank C, Cranmer LD, Robert C, Pavlick AC, Gonzalez R, Hodi FS, Ascierto PA, Salama AKS, Margolin KA, Gangadhar TC, Wei Z, Ebbinghaus S, Ibrahim N, Ribas A.
    Eur J Cancer; 2017 Nov 01; 86():37-45. PubMed ID: 28961465
    [Abstract] [Full Text] [Related]

  • 31. Ipilimumab-induced acute generalized exanthematous pustulosis in a patient with metastatic melanoma.
    Hwang SJ, Carlos G, Wakade D, Sharma R, Fernandez-Penas P.
    Melanoma Res; 2016 Aug 01; 26(4):417-20. PubMed ID: 27031538
    [Abstract] [Full Text] [Related]

  • 32. A case of ruptured hepatic metastases during pembrolizumab administration for cutaneous malignant melanoma.
    Igari S, Yamamoto M, Kikuchi N, Ohtsuka M, Yamamoto T.
    An Bras Dermatol; 2024 Aug 01; 99(3):450-451. PubMed ID: 38307808
    [No Abstract] [Full Text] [Related]

  • 33. A case of aseptic meningitis without neck rigidity occurring in a metastatic melanoma patient treated with ipilimumab.
    Oishi K, Nakao M, Maeda S, Matsushita T, Ikeda T, Yamada T, Takehara K, Hamaguchi Y.
    Eur J Dermatol; 2017 Apr 01; 27(2):193-194. PubMed ID: 28007669
    [No Abstract] [Full Text] [Related]

  • 34. [Acceptability and effectiveness of immunotherapy in patients with melanoma].
    Valnet-Rabier MB, Marcucci C, Limat S, Davani S, Aubin F, Nerich V.
    Therapie; 2019 Jun 01; 74(3):355-367. PubMed ID: 30193804
    [Abstract] [Full Text] [Related]

  • 35. Sarcoidosis-like syndrome and lymphadenopathy due to checkpoint inhibitors.
    Firwana B, Ravilla R, Raval M, Hutchins L, Mahmoud F.
    J Oncol Pharm Pract; 2017 Dec 01; 23(8):620-624. PubMed ID: 27590328
    [Abstract] [Full Text] [Related]

  • 36. Checkpoint inhibitor-induced sarcoid reaction mimicking bone metastases.
    Jespersen H, Bjursten S, Ny L, Levin M.
    Lancet Oncol; 2018 Jun 01; 19(6):e327. PubMed ID: 29893264
    [No Abstract] [Full Text] [Related]

  • 37. Rituximab in the treatment of pembrolizumab-induced myasthenia gravis.
    Crusz SM, Radunovic A, Shepherd S, Shah S, Newey V, Phillips M, Lim L, Powles T, Szlosarek PW, Shamash J, Rashid S.
    Eur J Cancer; 2018 Oct 01; 102():49-51. PubMed ID: 30138772
    [No Abstract] [Full Text] [Related]

  • 38. Metastatic melanoma and immunotherapy-related uveitis: an incidence in Northern Ireland.
    Dolaghan MJ, Oladipo B, Cooke CA, McAvoy CE.
    Eye (Lond); 2019 Oct 01; 33(10):1670-1672. PubMed ID: 31114029
    [No Abstract] [Full Text] [Related]

  • 39. BILATERAL CHOROIDAL DETACHMENTS SECONDARY TO IPILIMUMAB AND PEMBROLIZUMAB USE.
    O'Bryhim BE, Sychev Y, Rao PK.
    Retin Cases Brief Rep; 2021 May 01; 15(3):230-233. PubMed ID: 30044269
    [Abstract] [Full Text] [Related]

  • 40. Secondary haemophagocytic lymphohistiocytosis due to checkpoint inhibitor therapy.
    Chin CK, Hall S, Green C, Van Hazel G, Spagnolo D, Cheah CY.
    Eur J Cancer; 2019 Jul 01; 115():84-87. PubMed ID: 31129384
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.